Decoy Therapeutics Inc (DCOY)

$9.59 +4.07 (73.79%)
Market Cap 2.94M
Revenue (ttm) 0.00
Net Income (ttm) -12.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 12,685,649
Avg Vol 12,694
Day's Range N/A - N/A
Shares Out 532,000.00
Stochastic %K 2%
Beta 0.56
Analysts Sell
Price Target $30.01

Company Profile

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enha...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 913 5608
Website: decoytx.com
Address:
2450 Holcombe Blvd, Suite X, Houston, United States
WallStreet5
WallStreet5 Jun. 29 at 8:30 PM
$DCOY 🚀🚀🚀
0 · Reply
ProfessorDman1
ProfessorDman1 Jun. 29 at 8:29 PM
$DCOY $SDOT $TNMG $UPC $WHLR ( WHLR about to run now )
0 · Reply
IjustTradeiT
IjustTradeiT Jun. 29 at 8:15 PM
$DCOY 13 shorts golden
0 · Reply
IjustTradeiT
IjustTradeiT Jun. 29 at 8:15 PM
$DCOY lol trash
0 · Reply
ImagineWasTaken
ImagineWasTaken Jun. 29 at 8:02 PM
$DCOY 11.5 avg lets see a retrace to 7 before market open 🫡
0 · Reply
TALENT_ON_LOAN_FROM_GOD
TALENT_ON_LOAN_FROM_GOD Jun. 29 at 7:41 PM
$DCOY I’M MELTING…
0 · Reply
topstockalerts
topstockalerts Jun. 29 at 7:30 PM
Top Gainers $UPC $TNMG $DCOY $SDOT $DGNX
0 · Reply
ImagineWasTaken
ImagineWasTaken Jun. 29 at 7:25 PM
$DCOY someone wants out badly
0 · Reply
FlintstoneTrader
FlintstoneTrader Jun. 29 at 7:13 PM
That was a nice call man, Thanks for helping me bank :) Shoutout to @ElevenXProfits below for calling that early, Follow him 💯 Crazy type of move on $UPC $TMNG $DCOY $SDOT today wow
0 · Reply
NewsAndFilings
NewsAndFilings Jun. 29 at 7:06 PM
Sizzling Stocks Under $5: $UPC, $ANY, $NNBR, $DCOY Target AI Infrastructure, Data Centers, Pharmaceutical Innovation and Biotechnology Growth https://thestreetreports.com/sizzling-stocks-under-5-upc-any-nnbr-dcoy-target-ai-infrastructure-data-centers-pharmaceutical-innovation-and-biotechnology-growth/
0 · Reply
Latest News on DCOY
Why Is Penny Stock Decoy Therapeutics (DCOY) Up Today?

2026-06-29T17:47:20.000Z - 2 hours ago

Why Is Penny Stock Decoy Therapeutics (DCOY) Up Today?

Decoy Therapeutics Inc trading resumes

2026-06-29T13:40:52.000Z - 7 hours ago

Decoy Therapeutics Inc trading resumes

Decoy Therapeutics Inc trading halted, volatility trading pause

2026-06-29T13:35:22.000Z - 7 hours ago

Decoy Therapeutics Inc trading halted, volatility trading pause

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

Jun 26, 2026, 8:11 PM EDT - 2 days ago

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

Decoy Therapeutics Registration statement: Registration filing

Jun 15, 2026, 8:00 AM EDT - 14 days ago

Decoy Therapeutics Registration statement: Registration filing

Decoy Therapeutics files to sell 808,000 shares of common stock for holders

2026-06-15T10:16:08.000Z - 14 days ago

Decoy Therapeutics files to sell 808,000 shares of common stock for holders

Decoy Therapeutics Inc trading resumes

2026-06-09T15:56:35.000Z - 20 days ago

Decoy Therapeutics Inc trading resumes

Decoy Therapeutics Inc trading halted, volatility trading pause

2026-06-09T15:45:30.000Z - 20 days ago

Decoy Therapeutics Inc trading halted, volatility trading pause

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Jun 8, 2026, 8:00 AM EDT - 21 days ago

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Decoy Therapeutics Proxy statement: Proxy filing

Jun 4, 2026, 8:00 AM EDT - 25 days ago

Decoy Therapeutics Proxy statement: Proxy filing

Decoy Therapeutics Proxy statement: Proxy filing

Jun 4, 2026, 8:00 AM EDT - 25 days ago

Decoy Therapeutics Proxy statement: Proxy filing

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Jun 3, 2026, 8:00 AM EDT - 26 days ago

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Jun 1, 2026, 7:00 AM EDT - 4 weeks ago

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board

May 26, 2026, 8:15 AM EDT - 4 weeks ago

Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board

Decoy Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 7 weeks ago

Decoy Therapeutics Quarterly report: Q1 2026

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

Apr 27, 2026, 8:45 AM EDT - 2 months ago

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

Decoy Therapeutics Transcript: Status update

Apr 9, 2026, 4:00 PM EDT - 2 months ago

Decoy Therapeutics Transcript: Status update

Decoy Therapeutics Press release: Status update

Apr 9, 2026, 4:00 PM EDT - 2 months ago

Decoy Therapeutics Press release: Status update

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

Apr 9, 2026, 8:36 AM EDT - 2 months ago

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

Apr 6, 2026, 9:15 AM EDT - 3 months ago

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

Decoy Therapeutics regains Nasdaq compliance

2026-04-02T13:07:30.000Z - 3 months ago

Decoy Therapeutics regains Nasdaq compliance

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 2, 2026, 9:00 AM EDT - 3 months ago

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Decoy Therapeutics Annual report: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 3 months ago

Decoy Therapeutics Annual report: Q4 2025

Decoy Therapeutics enters collaboration with Quantori

2026-03-11T12:36:44.000Z - 3 months ago

Decoy Therapeutics enters collaboration with Quantori

GOOG GOOGL

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Mar 11, 2026, 8:30 AM EDT - 3 months ago

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Decoy Therapeutics Inc trading halted, news pending

2026-03-07T00:50:47.000Z - 4 months ago

Decoy Therapeutics Inc trading halted, news pending

Decoy Therapeutics announces 1-for-12 reverse stock split

2026-03-05T13:54:29.000Z - 4 months ago

Decoy Therapeutics announces 1-for-12 reverse stock split

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Mar 5, 2026, 8:30 AM EST - 4 months ago

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Feb 11, 2026, 9:00 AM EST - 4 months ago

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 5 months ago

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Feb 4, 2026, 9:02 AM EST - 5 months ago

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Decoy Therapeutics initiated with a Buy at Ladenburg

2026-01-23T11:40:21.000Z - 5 months ago

Decoy Therapeutics initiated with a Buy at Ladenburg

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Jan 13, 2026, 8:15 AM EST - 5 months ago

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Decoy Therapeutics Proxy statement: Proxy Filing

Jan 9, 2026, 7:00 AM EST - 6 months ago

Decoy Therapeutics Proxy statement: Proxy Filing

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Jan 7, 2026, 8:45 AM EST - 6 months ago

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Decoy Therapeutics Proxy statement: Proxy Filing

Dec 29, 2025, 7:00 AM EST - 6 months ago

Decoy Therapeutics Proxy statement: Proxy Filing

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Dec 19, 2025, 11:12 AM EST - 6 months ago

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Decoy Therapeutics Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 6 months ago

Decoy Therapeutics Proxy statement: Proxy Filing

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Dec 18, 2025, 7:50 AM EST - 6 months ago

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Dec 1, 2025, 8:00 AM EST - 7 months ago

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Nov 19, 2025, 2:42 PM EST - 7 months ago

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Decoy Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 8 months ago

Decoy Therapeutics Quarterly report: Q3 2025

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Nov 13, 2025, 8:45 AM EST - 8 months ago

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Nov 11, 2025, 9:18 AM EST - 8 months ago

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Decoy Therapeutics Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 8 months ago

Decoy Therapeutics Proxy statement: Proxy Filing

Decoy Therapeutics Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 8 months ago

Decoy Therapeutics Proxy statement: Proxy Filing

Decoy Therapeutics Registration statement: Registration Filing

Oct 21, 2025, 7:00 AM EDT - 8 months ago

Decoy Therapeutics Registration statement: Registration Filing

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Oct 13, 2025, 8:45 AM EDT - 9 months ago

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Decoy Therapeutics Registration statement: Registration Filing

Sep 23, 2025, 8:00 AM EDT - 9 months ago

Decoy Therapeutics Registration statement: Registration Filing

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 9, 2025, 8:00 AM EDT - 10 months ago

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Decoy Therapeutics Registration statement: Registration Filing

Aug 15, 2025, 8:00 AM EDT - 11 months ago

Decoy Therapeutics Registration statement: Registration Filing

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Decoy Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 11 months ago

Decoy Therapeutics Quarterly report: Q2 2025

Decoy Therapeutics Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 11 months ago

Decoy Therapeutics Registration statement: Registration Filing

Decoy Therapeutics Registration statement: Registration Filing

Jul 31, 2025, 8:00 AM EDT - 11 months ago

Decoy Therapeutics Registration statement: Registration Filing

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Jul 14, 2025, 8:30 AM EDT - 1 year ago

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Decoy Therapeutics Registration statement: Registration Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Registration statement: Registration Filing

Decoy Therapeutics Proxy statement: Proxy Filing

May 27, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing

Decoy Therapeutics Proxy statement: Proxy Filing

May 27, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing

Decoy Therapeutics Registration statement: Registration Filing

May 22, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Registration statement: Registration Filing

Decoy Therapeutics Proxy statement: Proxy Filing

May 15, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing

Decoy Therapeutics Proxy statement: Proxy Filing

May 15, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing

Decoy Therapeutics Quarterly report: Q1 2025

May 13, 2025, 6:00 PM EDT - 1 year ago

Decoy Therapeutics Quarterly report: Q1 2025

Decoy Therapeutics Registration statement: Registration Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Registration statement: Registration Filing

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Decoy Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Decoy Therapeutics Earnings release: Q4 2024

Decoy Therapeutics Annual report: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Decoy Therapeutics Annual report: Q4 2024

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Feb 3, 2025, 8:00 AM EST - 1 year ago

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Decoy Therapeutics Registration statement: Registration Filing

Jan 21, 2025, 7:00 AM EST - 1 year ago

Decoy Therapeutics Registration statement: Registration Filing

Decoy Therapeutics Registration statement: Registration Filing

Dec 16, 2024, 7:00 AM EST - 1 year ago

Decoy Therapeutics Registration statement: Registration Filing

Decoy Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Decoy Therapeutics Quarterly report: Q3 2024

Decoy Therapeutics Proxy statement: Proxy Filing

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing

Decoy Therapeutics Proxy statement: Proxy Filing

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing

Decoy Therapeutics Quarterly report: Q2 2024

Sep 7, 2024, 6:00 PM EDT - 1 year ago

Decoy Therapeutics Quarterly report: Q2 2024

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Jun 12, 2024, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Decoy Therapeutics Quarterly report: Q1 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Decoy Therapeutics Quarterly report: Q1 2024

Decoy Therapeutics Earnings release: Q1 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Decoy Therapeutics Earnings release: Q1 2024

Decoy Therapeutics Proxy statement: Proxy Filing

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Decoy Therapeutics Proxy statement: Proxy Filing

Decoy Therapeutics Proxy statement: Proxy Filing

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Decoy Therapeutics Proxy statement: Proxy Filing

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 22, 2024, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Decoy Therapeutics Earnings release: Q4 2023

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Decoy Therapeutics Earnings release: Q4 2023

Decoy Therapeutics Annual report: Q4 2023

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Decoy Therapeutics Annual report: Q4 2023

Decoy Therapeutics Proxy statement: Proxy Filing

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Decoy Therapeutics Proxy statement: Proxy Filing

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Jan 3, 2024, 8:30 AM EST - 2 years ago

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Decoy Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Decoy Therapeutics Quarterly report: Q3 2023

Decoy Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Decoy Therapeutics Earnings release: Q3 2023

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Nov 7, 2023, 8:30 AM EST - 2 years ago

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 10, 2023, 4:05 PM EDT - 3 years ago

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Decoy Therapeutics Quarterly report: Q2 2023

Aug 10, 2023, 4:00 PM EDT - 3 years ago

Decoy Therapeutics Quarterly report: Q2 2023

Decoy Therapeutics Earnings release: Q2 2023

Aug 10, 2023, 4:00 PM EDT - 3 years ago

Decoy Therapeutics Earnings release: Q2 2023

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Jul 11, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Jun 12, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Decoy Therapeutics Registration statement: Registration Filing

Jun 1, 2023, 8:00 AM EDT - 3 years ago

Decoy Therapeutics Registration statement: Registration Filing

Decoy Therapeutics Registration statement: Registration Filing

May 26, 2023, 8:00 AM EDT - 3 years ago

Decoy Therapeutics Registration statement: Registration Filing

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 16, 2023, 4:05 PM EDT - 3 years ago

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 12, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Decoy Therapeutics Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Decoy Therapeutics Quarterly report: Q1 2023

Decoy Therapeutics Earnings release: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Decoy Therapeutics Earnings release: Q1 2023

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

May 9, 2023, 8:17 AM EDT - 3 years ago

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

May 9, 2023, 8:00 AM EDT - 3 years ago

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

May 1, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

Decoy Therapeutics Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

Decoy Therapeutics Proxy statement: Proxy Filing

Decoy Therapeutics Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

Decoy Therapeutics Proxy statement: Proxy Filing

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Apr 4, 2023, 4:02 PM EDT - 3 years ago

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 27, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Decoy Therapeutics Earnings release: Q4 2022

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Decoy Therapeutics Earnings release: Q4 2022

Decoy Therapeutics Annual report: Q4 2022

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Decoy Therapeutics Annual report: Q4 2022

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Mar 15, 2023, 11:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Feb 16, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 27, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

WallStreet5
WallStreet5 Jun. 29 at 8:30 PM
$DCOY 🚀🚀🚀
0 · Reply
ProfessorDman1
ProfessorDman1 Jun. 29 at 8:29 PM
$DCOY $SDOT $TNMG $UPC $WHLR ( WHLR about to run now )
0 · Reply
IjustTradeiT
IjustTradeiT Jun. 29 at 8:15 PM
$DCOY 13 shorts golden
0 · Reply
IjustTradeiT
IjustTradeiT Jun. 29 at 8:15 PM
$DCOY lol trash
0 · Reply
ImagineWasTaken
ImagineWasTaken Jun. 29 at 8:02 PM
$DCOY 11.5 avg lets see a retrace to 7 before market open 🫡
0 · Reply
TALENT_ON_LOAN_FROM_GOD
TALENT_ON_LOAN_FROM_GOD Jun. 29 at 7:41 PM
$DCOY I’M MELTING…
0 · Reply
topstockalerts
topstockalerts Jun. 29 at 7:30 PM
Top Gainers $UPC $TNMG $DCOY $SDOT $DGNX
0 · Reply
ImagineWasTaken
ImagineWasTaken Jun. 29 at 7:25 PM
$DCOY someone wants out badly
0 · Reply
FlintstoneTrader
FlintstoneTrader Jun. 29 at 7:13 PM
That was a nice call man, Thanks for helping me bank :) Shoutout to @ElevenXProfits below for calling that early, Follow him 💯 Crazy type of move on $UPC $TMNG $DCOY $SDOT today wow
0 · Reply
NewsAndFilings
NewsAndFilings Jun. 29 at 7:06 PM
Sizzling Stocks Under $5: $UPC, $ANY, $NNBR, $DCOY Target AI Infrastructure, Data Centers, Pharmaceutical Innovation and Biotechnology Growth https://thestreetreports.com/sizzling-stocks-under-5-upc-any-nnbr-dcoy-target-ai-infrastructure-data-centers-pharmaceutical-innovation-and-biotechnology-growth/
0 · Reply
ImagineWasTaken
ImagineWasTaken Jun. 29 at 6:53 PM
$DCOY 9.0 close, maybe even 8 or 7 if structure is broken.
0 · Reply
ProfessorDman1
ProfessorDman1 Jun. 29 at 6:52 PM
$WHLR short squeeze run incoming here .. another botttom chart 1.32-1.35 $UPC $SDOT $TNMG $DCOY
0 · Reply
FinanceLegacy
FinanceLegacy Jun. 29 at 6:40 PM
$CTM let’s goooo getting found power hour can push over .80 interesting volume $259M backloggg just like $UPC $DCOY 🤩🤩
0 · Reply
FinanceLegacy
FinanceLegacy Jun. 29 at 6:06 PM
$CTM many contracts $230 million backlog .73c doesn’t make sense to meeee should gap over $1 let’s gooo🤩🤩🤩 Watching $BTOG $UPC $TNMG $DCOY
1 · Reply
FinanceLegacy
FinanceLegacy Jun. 29 at 5:58 PM
$CTM heading towards .80 power hour for the squeezeee can go like $UPC $TNMG $DCOY Same ingredients 🤩🤩
0 · Reply
topstockalerts
topstockalerts Jun. 29 at 5:56 PM
Top Gainers $UPC $TNMG $DCOY $DGNX $SDOT
0 · Reply
NightShiftTravelNurse
NightShiftTravelNurse Jun. 29 at 5:55 PM
$DCOY
0 · Reply
FinanceLegacy
FinanceLegacy Jun. 29 at 5:22 PM
$CTM massive budget to modernize the military about to get squeezed here flagging same as $SDOT $DCOY was banging on the table before they popped 🤩🤩🤩
0 · Reply
Imaluckytrader69
Imaluckytrader69 Jun. 29 at 5:21 PM
$DCOY common back $18
0 · Reply
porta111
porta111 Jun. 29 at 5:12 PM
$DCOY short squeeze coming
1 · Reply
ImagineWasTaken
ImagineWasTaken Jun. 29 at 5:10 PM
$DCOY how the bulls on this forum act. wouldn't be surprised to see an SI over 50% tomorrow 🤣🤣
0 · Reply
Zohan_69
Zohan_69 Jun. 29 at 5:07 PM
$DCOY
0 · Reply